Vincerx Pharma, Inc.

NasdaqCM VINC

Vincerx Pharma, Inc. Dividend Yield on February 05, 2025

Vincerx Pharma, Inc. Dividend Yield is NA on February 05, 2025, a NA change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Vincerx Pharma, Inc. 52-week high Dividend Yield is NA on February 05, 2025, which is NA below the current Dividend Yield.
Vincerx Pharma, Inc. 52-week low Dividend Yield is NA on February 05, 2025, which is NA below the current Dividend Yield.
Vincerx Pharma, Inc. average Dividend Yield for the last 52 weeks is NA.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqCM: VINC

Vincerx Pharma, Inc.

CEO	Dr. Raquel E. Izumi Ph.D.
IPO Date	May 27, 2020
Location	United States
Headquarters	260 Sheridan Avenue
Employees	42
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Key trends

Past 5 years